Suggested Remit: To appraise the clinical and cost effectiveness of fostemsavir within its proposed marketing authorisation for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen.
Status Proposed
Process STA 2018
ID number 2726

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 17 June 2020 - 15 July 2020
Scoping workshop 03 August 2020 (10:00)

Project Team

Project lead Michelle Adhemar

Email enquiries

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance